Correlation between work impairment, scores of rhinitis severity and asthma using the MASK-air® App

Annabelle Bédard; Josep M. Antó; Joao A. Fonseca; Sylvie Arnavielhe; Claus Bachert; Anna Bedbrook; Carsten Bindslev-Jensen; Sinthia Bosnic-Anticevich; Victoria Cardona; Alvaro A. Cruz; Wytske J. Fokkens; Judith Garcia-Aymerich; Peter W. Hellings; Juan C. Ivancevich; Ludger Klimek; Piotr Kuna; Violeta Kvedariene; Désirée Larenas-Linnemann; Erik Melén; Ricardo Monti; Ralf Mösges; Joaquim Mullol; Nikos G. Papadopoulos; Nhân Pham-Thi; Boleslaw Samolinski; Peter V. Tomazic; Sanna Toppila-Salmi; Maria Teresa Ventura; Arzu Yorgancioglu; Jean Bousquet; Oliver Pfaar; Xavier Basagaña; the MASK study groupJr

doi:10.1111/all.14204

Correlation between work impairment, scores of rhinitis severity and asthma using the MASK-air^® App

Annabelle Bédard, Josep M. Antó, Joao A. Fonseca, Sylvie Arnavielhe, Claus Bachert, Anna Bedbrook, Carsten Bindslev-Jensen, Sinthia Bosnic-Anticevich, Victoria Cardona, Alvaro A. Cruz, Wytske J. Fokkens, Judith Garcia-Aymerich, Peter W. Hellings, Juan C. Ivancevich, Ludger Klimek, Piotr Kuna, Violeta Kvedariene, Désirée Larenas-Linnemann, Erik Melén, Ricardo MontiRalf Mösges, Joaquim Mullol, Nikos G. Papadopoulos, Nhân Pham-Thi, Boleslaw Samolinski, Peter V. Tomazic, Sanna Toppila-Salmi, Maria Teresa Ventura, Arzu Yorgancioglu, Jean Bousquet, Oliver Pfaar, Xavier Basagaña, the MASK study groupJr

Research output: Contribution to journal › Article › Research › peer-review

38 Citations (Scopus)

Abstract

Background: In allergic rhinitis, a relevant outcome providing information on the effectiveness of interventions is needed. In MASK-air (Mobile Airways Sentinel Network), a visual analogue scale (VAS) for work is used as a relevant outcome. This study aimed to assess the performance of the work VAS work by comparing VAS work with other VAS measurements and symptom-medication scores obtained concurrently. Methods: All consecutive MASK-air users in 23 countries from 1 June 2016 to 31 October 2018 were included (14 189 users; 205 904 days). Geolocalized users self-assessed daily symptom control using the touchscreen functionality on their smart phone to click on VAS scores (ranging from 0 to 100) for overall symptoms (global), nose, eyes, asthma and work. Two symptom-medication scores were used: the modified EAACI CSMS score and the MASK control score for rhinitis. To assess data quality, the intra-individual response variability (IRV) index was calculated. Results: A strong correlation was observed between VAS work and other VAS. The highest levels for correlation with VAS work and variance explained in VAS work were found with VAS global, followed by VAS nose, eye and asthma. In comparison with VAS global, the mCSMS and MASK control score showed a lower correlation with VAS work. Results are unlikely to be explained by a low quality of data arising from repeated VAS measures. Conclusions: VAS work correlates with other outcomes (VAS global, nose, eye and asthma) but less well with a symptom-medication score. VAS work should be considered as a potentially useful AR outcome in intervention studies.

Original language	English
Pages (from-to)	1672-1688
Number of pages	17
Journal	Allergy
Volume	75
Issue number	7
DOIs	https://doi.org/10.1111/all.14204
Publication status	Published - 1 Jul 2020

Keywords

asthma
MASK
rhinitis
score
visual analogue scale

Access to Document

10.1111/all.14204

Cite this

Bédard, A., Antó, J. M., Fonseca, J. A., Arnavielhe, S., Bachert, C., Bedbrook, A., Bindslev-Jensen, C., Bosnic-Anticevich, S., Cardona, V., Cruz, A. A., Fokkens, W. J., Garcia-Aymerich, J., Hellings, P. W., Ivancevich, J. C., Klimek, L., Kuna, P., Kvedariene, V., Larenas-Linnemann, D., Melén, E., ... the MASK study groupJr (2020). Correlation between work impairment, scores of rhinitis severity and asthma using the MASK-air^® App. Allergy, 75(7), 1672-1688. https://doi.org/10.1111/all.14204

@article{a3bbd73055ab470f95250d734e9fff40,

title = "Correlation between work impairment, scores of rhinitis severity and asthma using the MASK-air{\textregistered} App",

abstract = "Background: In allergic rhinitis, a relevant outcome providing information on the effectiveness of interventions is needed. In MASK-air (Mobile Airways Sentinel Network), a visual analogue scale (VAS) for work is used as a relevant outcome. This study aimed to assess the performance of the work VAS work by comparing VAS work with other VAS measurements and symptom-medication scores obtained concurrently. Methods: All consecutive MASK-air users in 23 countries from 1 June 2016 to 31 October 2018 were included (14 189 users; 205 904 days). Geolocalized users self-assessed daily symptom control using the touchscreen functionality on their smart phone to click on VAS scores (ranging from 0 to 100) for overall symptoms (global), nose, eyes, asthma and work. Two symptom-medication scores were used: the modified EAACI CSMS score and the MASK control score for rhinitis. To assess data quality, the intra-individual response variability (IRV) index was calculated. Results: A strong correlation was observed between VAS work and other VAS. The highest levels for correlation with VAS work and variance explained in VAS work were found with VAS global, followed by VAS nose, eye and asthma. In comparison with VAS global, the mCSMS and MASK control score showed a lower correlation with VAS work. Results are unlikely to be explained by a low quality of data arising from repeated VAS measures. Conclusions: VAS work correlates with other outcomes (VAS global, nose, eye and asthma) but less well with a symptom-medication score. VAS work should be considered as a potentially useful AR outcome in intervention studies.",

keywords = "asthma, MASK, rhinitis, score, visual analogue scale",

author = "Annabelle B{\'e}dard and Ant{\'o}, {Josep M.} and Fonseca, {Joao A.} and Sylvie Arnavielhe and Claus Bachert and Anna Bedbrook and Carsten Bindslev-Jensen and Sinthia Bosnic-Anticevich and Victoria Cardona and Cruz, {Alvaro A.} and Fokkens, {Wytske J.} and Judith Garcia-Aymerich and Hellings, {Peter W.} and Ivancevich, {Juan C.} and Ludger Klimek and Piotr Kuna and Violeta Kvedariene and D{\'e}sir{\'e}e Larenas-Linnemann and Erik Mel{\'e}n and Ricardo Monti and Ralf M{\"o}sges and Joaquim Mullol and Papadopoulos, {Nikos G.} and Nh{\^a}n Pham-Thi and Boleslaw Samolinski and Tomazic, {Peter V.} and Sanna Toppila-Salmi and Ventura, {Maria Teresa} and Arzu Yorgancioglu and Jean Bousquet and Oliver Pfaar and Xavier Basaga{\~n}a and W. Aberer and I. Agache and Akdis, {C. A.} and M. Akdis and Aliberti, {M. R.} and R. Almeida and F. Amat and R. Angles and I. Annesi-Maesano and Ansotegui, {I. J.} and S. Arnavielle and E. Asayag and A. Asarnoj and H. Arshad and F. Avolio and E. Bacci and I. Baiardini and C. Barbara and M. Barbagallo and I. Baroni and Barreto, {B. A.} and Bateman, {E. D.} and M. Bedolla-Barajas and M. Bewick and B. Begh{\'e} and Bel, {E. H.} and Bergmann, {K. C.} and Bennoor, {K. S.} and M. Benson and L. Bertorello and Bia{\l}oszewski, {A. Z.} and T. Bieber and S. Bialek and L. Bjermer and H. Blain and F. Blasi and A. Blua and {Bochenska Marciniak}, M. and I. Bogus-Buczynska and Boner, {A. L.} and M. Bonini and S. Bonini and I. Bosse and J. Bouchard and Boulet, {L. P.} and R. Bourret and Bousquet, {P. J.} and F. Braido and V. Briedis and Brightling, {C. E.} and J. Brozek and C. Bucca and R. Buhl and R. Buonaiuto and C. Panaitescu and {Burguete Caba{\~n}as}, {M. T.} and E. Burte and A. Bush and F. Caballero-Fonseca and D. Caillaud and D. Caimmi and Calderon, {M. A.} and Camargos, {P. A.M.} and T. Camuzat and G. Canfora and Canonica, {G. W.} and Carlsen, {K. H.} and P. Carreiro-Martins and Carriazo, {A. M.} and W. Carr and C. Cartier and T. Casale and G. Castellano and L. Cecchi and Cepeda, {A. M.} and Chavannes, {N. H.} and Y. Chen and R. Chiron and T. Chivato and E. Chkhartishvili and Chuchalin, {A. G.} and Chung, {K. F.} and Ciaravolo, {M. M.} and A. Ciceran and C. Cingi and G. Ciprandi and {Carvalho Coehlo}, {A. C.} and L. Colas and E. Colgan and J. Coll and D. Conforti and J. Constantinidis and {Correia de Sousa}, J. and Cort{\'e}s-Grimaldo, {R. M.} and F. Corti and E. Costa and Costa-Dominguez, {M. C.} and Courbis, {A. L.} and L. Cox and M. Crescenzo and A. Custovic and W. Czarlewski and Dahlen, {S. E.} and G. D'Amato and C. Dario and {da Silva}, J. and Y. Dauvilliers and U. Darsow and {De Blay}, F. and {De Carlo}, G. and T. Dedeu and {de F{\'a}tima Emerson}, M. and {De Feo}, G. and {De Vries}, G. and {De Martino}, B. and {Motta Rubini}, {N. P.} and D. Deleanu and Denburg, {J. A.} and P. Devillier and {Di Capua Ercolano}, S. and {Di Carluccio}, N. and A. Didier and D. Dokic and Dominguez-Silva, {M. G.} and H. Douagui and G. Dray and R. Dubakiene and Durham, {S. R.} and {Du Toit}, G. and Dykewicz, {M. S.} and Y. El-Gamal and P. Eklund and E. Eller and R. Emuzyte and J. Farrell and A. Farsi and {Ferreira de Mello}, J. and J. Ferrero and A. Fink-Wagner and A. Fiocchi and Fontaine, {J. F.} and S. Forti and Fuentes-Perez, {J. M.} and G{\'a}lvez-Romero, {J. L.} and A. Gamkrelidze and Garc{\'i}a-Cobas, {C. Y.} and Garcia-Cruz, {M. H.} and B. Gemicioğlu and S. Genova and G. Christoff and Gereda, {J. E.} and {Gerth van Wijk}, R. and Gomez, {R. M.} and J. G{\'o}mez-Vera and {Gonz{\'a}lez Diaz}, S. and M. Gotua and I. Grisle and M. Guidacci and Guldemond, {N. A.} and Z. Gutter and Guzm{\'a}n, {M. A.} and T. Haahtela and J. Hajjam and L. Hern{\'a}ndez and Hourihane, {J. O.B.} and Huerta-Villalobos, {Y. R.} and M. Humbert and G. Iaccarino and M. Illario and Z. Ispayeva and Jares, {E. J.} and E. Jassem and Johnston, {S. L.} and G. Joos and Jung, {K. S.} and J. Just and M. Jutel and I. Kaidashev and O. Kalayci and Kalyoncu, {A. F.} and J. Karjalainen and P. Kardas and T. Keil and Keith, {P. K.} and M. Khaitov and N. Khaltaev and J. Kleine-Tebbe and Kowalski, {M. L.} and M. Kuitunen and I. Kull and M. Kupczyk and E. Krzych-Fa{\l}ta and P. Lacwik and D. Laune and D. Lauri and J. Lavrut and Le, {L. T.T.} and M. Lessa and G. Levato and J. Li and P. Lieberman and A. Lipiec and B. Lipworth and {Lodrup Carlsen}, {K. C.} and R. Louis and O. Louren{\c c}o and Luna-Pech, {J. A.} and A. Magnan and B. Mahboub and D. Maier and A. Mair and I. Majer and J. Malva and E. Mandajieva and P. Manning and O'Hehir, {R. E.} and R. Puy and C. Zubrinich and {the MASK study groupJr}",

note = "Funding Information: Dr Bousquet reports personal fees from Chiesi, Cipla, Hikma, Menarini, Mundipharma, Mylan, Novartis, Purina, Sanofi‐Aventis, Takeda, Teva, Uriach, other from KYomed‐Innov, outside the submitted work. Dr Bosnic‐Anticevich reports grants from TEVA, personal fees from TEVA, AstraZeneca, Boehringer Ingelheim, GSK, Sanofi, Mylan, outside the submitted work. Dr Cardona reports personal fees from ALK, Allergopharma, Allergy Therapeutics, Diater, LETI, Thermofisher, Stallergenes, outside the submitted work. Dr Fonseca being a partner in a company developing mobile technologies for monitoring airways diseases. Dr Hellings reports grants and personal fees from Mylan, during the conduct of the study; personal fees from Sanofi, Allergopharma, Stallergenes, outside the submitted work. Dr Ivancevich reports personal fees from Faes Farma, Eurofarma Argentina, other from Sanofi, Laboratorios Casasco, personal fees from, outside the submitted work. Dr Kuna reports personal fees from Adamed, AstraZeneca, Boehringer Ingelheim, Hal, Chiesi, Novartis, Berlin Chemie Menarini, outside the submitted work. Dr Kvedariene reports personal fees from GSK, non‐financial support from StallergenGreer, Mylan, AstraZeneca, Dimuna, Norameda, outside the submitted work. Dr Larenas Linnemann reports personal fees from Amstrong, Astrazeneca, Boehringer Ingelheim, Chiesi, DBV Technologies, Grunenthal, GSK, MEDA, Menarini, MSD, Novartis, Pfizer, Novartis, Sanofi, Siegfried, UCB. grants from Sanofi, Astrazeneca, Novartis, UCB, GSK, TEVA, Boehringer Ingelheim, Chiesi.outside the submitted work. Dr MULLOL reports personal fees from SANOFI‐Genzyme‐Regeneron, ALK‐Abell{\'o} A/S, Menarini Group, MSD, GlaxoSmithKline, Novartis, GENENTECH ‐ Roche_Novartis, grants and personal fees from UCB Pharma, MYLAN‐MEDA Pharma, URIACH Group, outside the submitted work. Dr Papadopoulos reports personal fees from Novartis, Nutricia, HAL, MENARINI/FAES FARMA, SANOFI, MYLAN/MEDA, BIOMAY, AstraZeneca, GSK, MSD, ASIT BIOTECH, Boehringer Ingelheim, grants from Gerolymatos International SA, Capricare, outside the submitted work. Dr Bousquet reports personal fees from Chiesi, Cipla, Hikma, Menarini, Mundipharma, Mylan, Novartis, Purina, Sanofi‐Aventis, Takeda, Teva, Uriach, other from KYomed‐Innov, outside the submitted work. Dr Pfaar reports personal fees from MEDA Pharma/MYLAN, ASIT Biotech Tools SA Laboratorios LETI/LETI Pharma, Anergis S.A, Mobile Chamber Experts (a GALEN Partner), Indoor Biotechnologies, Astellas Pharma Global, grants and personal fees from ALK‐Abell{\'o}, Allergopharma, Stallergenes Greer, HAL Allergy Holding BV/HAL Allergie GmbH, Bencard Allergie GmbH/Allergy Therapeutics, Lofarma, grants from Biomay, Nuvo, Circassia, from, Glaxo Smith Kline, outside the submitted work. 2 Publisher Copyright: {\textcopyright} 2020 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.",

year = "2020",

month = jul,

day = "1",

doi = "10.1111/all.14204",

language = "English",

volume = "75",

pages = "1672--1688",

journal = "Allergy",

issn = "0105-4538",

publisher = "Wiley-Blackwell",

number = "7",

}

Bédard, A, Antó, JM, Fonseca, JA, Arnavielhe, S, Bachert, C, Bedbrook, A, Bindslev-Jensen, C, Bosnic-Anticevich, S, Cardona, V, Cruz, AA, Fokkens, WJ, Garcia-Aymerich, J, Hellings, PW, Ivancevich, JC, Klimek, L, Kuna, P, Kvedariene, V, Larenas-Linnemann, D, Melén, E, Monti, R, Mösges, R, Mullol, J, Papadopoulos, NG, Pham-Thi, N, Samolinski, B, Tomazic, PV, Toppila-Salmi, S, Ventura, MT, Yorgancioglu, A, Bousquet, J, Pfaar, O, Basagaña, X & the MASK study groupJr 2020, 'Correlation between work impairment, scores of rhinitis severity and asthma using the MASK-air^® App', Allergy, vol. 75, no. 7, pp. 1672-1688. https://doi.org/10.1111/all.14204

TY - JOUR

T1 - Correlation between work impairment, scores of rhinitis severity and asthma using the MASK-air® App

AU - Bédard, Annabelle

AU - Antó, Josep M.

AU - Fonseca, Joao A.

AU - Arnavielhe, Sylvie

AU - Bachert, Claus

AU - Bedbrook, Anna

AU - Bindslev-Jensen, Carsten

AU - Bosnic-Anticevich, Sinthia

AU - Cardona, Victoria

AU - Cruz, Alvaro A.

AU - Fokkens, Wytske J.

AU - Garcia-Aymerich, Judith

AU - Hellings, Peter W.

AU - Ivancevich, Juan C.

AU - Klimek, Ludger

AU - Kuna, Piotr

AU - Kvedariene, Violeta

AU - Larenas-Linnemann, Désirée

AU - Melén, Erik

AU - Monti, Ricardo

AU - Mösges, Ralf

AU - Mullol, Joaquim

AU - Papadopoulos, Nikos G.

AU - Pham-Thi, Nhân

AU - Samolinski, Boleslaw

AU - Tomazic, Peter V.

AU - Toppila-Salmi, Sanna

AU - Ventura, Maria Teresa

AU - Yorgancioglu, Arzu

AU - Bousquet, Jean

AU - Pfaar, Oliver

AU - Basagaña, Xavier

AU - Aberer, W.

AU - Agache, I.

AU - Akdis, C. A.

AU - Akdis, M.

AU - Aliberti, M. R.

AU - Almeida, R.

AU - Amat, F.

AU - Angles, R.

AU - Annesi-Maesano, I.

AU - Ansotegui, I. J.

AU - Arnavielle, S.

AU - Asayag, E.

AU - Asarnoj, A.

AU - Arshad, H.

AU - Avolio, F.

AU - Bacci, E.

AU - Baiardini, I.

AU - Barbara, C.

AU - Barbagallo, M.

AU - Baroni, I.

AU - Barreto, B. A.

AU - Bateman, E. D.

AU - Bedolla-Barajas, M.

AU - Bewick, M.

AU - Beghé, B.

AU - Bel, E. H.

AU - Bergmann, K. C.

AU - Bennoor, K. S.

AU - Benson, M.

AU - Bertorello, L.

AU - Białoszewski, A. Z.

AU - Bieber, T.

AU - Bialek, S.

AU - Bjermer, L.

AU - Blain, H.

AU - Blasi, F.

AU - Blua, A.

AU - Bochenska Marciniak, M.

AU - Bogus-Buczynska, I.

AU - Boner, A. L.

AU - Bonini, M.

AU - Bonini, S.

AU - Bosse, I.

AU - Bouchard, J.

AU - Boulet, L. P.

AU - Bourret, R.

AU - Bousquet, P. J.

AU - Braido, F.

AU - Briedis, V.

AU - Brightling, C. E.

AU - Brozek, J.

AU - Bucca, C.

AU - Buhl, R.

AU - Buonaiuto, R.

AU - Panaitescu, C.

AU - Burguete Cabañas, M. T.

AU - Burte, E.

AU - Bush, A.

AU - Caballero-Fonseca, F.

AU - Caillaud, D.

AU - Caimmi, D.

AU - Calderon, M. A.

AU - Camargos, P. A.M.

AU - Camuzat, T.

AU - Canfora, G.

AU - Canonica, G. W.

AU - Carlsen, K. H.

AU - Carreiro-Martins, P.

AU - Carriazo, A. M.

AU - Carr, W.

AU - Cartier, C.

AU - Casale, T.

AU - Castellano, G.

AU - Cecchi, L.

AU - Cepeda, A. M.

AU - Chavannes, N. H.

AU - Chen, Y.

AU - Chiron, R.

AU - Chivato, T.

AU - Chkhartishvili, E.

AU - Chuchalin, A. G.

AU - Chung, K. F.

AU - Ciaravolo, M. M.

AU - Ciceran, A.

AU - Cingi, C.

AU - Ciprandi, G.

AU - Carvalho Coehlo, A. C.

AU - Colas, L.

AU - Colgan, E.

AU - Coll, J.

AU - Conforti, D.

AU - Constantinidis, J.

AU - Correia de Sousa, J.

AU - Cortés-Grimaldo, R. M.

AU - Corti, F.

AU - Costa, E.

AU - Costa-Dominguez, M. C.

AU - Courbis, A. L.

AU - Cox, L.

AU - Crescenzo, M.

AU - Custovic, A.

AU - Czarlewski, W.

AU - Dahlen, S. E.

AU - D'Amato, G.

AU - Dario, C.

AU - da Silva, J.

AU - Dauvilliers, Y.

AU - Darsow, U.

AU - De Blay, F.

AU - De Carlo, G.

AU - Dedeu, T.

AU - de Fátima Emerson, M.

AU - De Feo, G.

AU - De Vries, G.

AU - De Martino, B.

AU - Motta Rubini, N. P.

AU - Deleanu, D.

AU - Denburg, J. A.

AU - Devillier, P.

AU - Di Capua Ercolano, S.

AU - Di Carluccio, N.

AU - Didier, A.

AU - Dokic, D.

AU - Dominguez-Silva, M. G.

AU - Douagui, H.

AU - Dray, G.

AU - Dubakiene, R.

AU - Durham, S. R.

AU - Du Toit, G.

AU - Dykewicz, M. S.

AU - El-Gamal, Y.

AU - Eklund, P.

AU - Eller, E.

AU - Emuzyte, R.

AU - Farrell, J.

AU - Farsi, A.

AU - Ferreira de Mello, J.

AU - Ferrero, J.

AU - Fink-Wagner, A.

AU - Fiocchi, A.

AU - Fontaine, J. F.

AU - Forti, S.

AU - Fuentes-Perez, J. M.

AU - Gálvez-Romero, J. L.

AU - Gamkrelidze, A.

AU - García-Cobas, C. Y.

AU - Garcia-Cruz, M. H.

AU - Gemicioğlu, B.

AU - Genova, S.

AU - Christoff, G.

AU - Gereda, J. E.

AU - Gerth van Wijk, R.

AU - Gomez, R. M.

AU - Gómez-Vera, J.

AU - González Diaz, S.

AU - Gotua, M.

AU - Grisle, I.

AU - Guidacci, M.

AU - Guldemond, N. A.

AU - Gutter, Z.

AU - Guzmán, M. A.

AU - Haahtela, T.

AU - Hajjam, J.

AU - Hernández, L.

AU - Hourihane, J. O.B.

AU - Huerta-Villalobos, Y. R.

AU - Humbert, M.

AU - Iaccarino, G.

AU - Illario, M.

AU - Ispayeva, Z.

AU - Jares, E. J.

AU - Jassem, E.

AU - Johnston, S. L.

AU - Joos, G.

AU - Jung, K. S.

AU - Just, J.

AU - Jutel, M.

AU - Kaidashev, I.

AU - Kalayci, O.

AU - Kalyoncu, A. F.

AU - Karjalainen, J.

AU - Kardas, P.

AU - Keil, T.

AU - Keith, P. K.

AU - Khaitov, M.

AU - Khaltaev, N.

AU - Kleine-Tebbe, J.

AU - Kowalski, M. L.

AU - Kuitunen, M.

AU - Kull, I.

AU - Kupczyk, M.

AU - Krzych-Fałta, E.

AU - Lacwik, P.

AU - Laune, D.

AU - Lauri, D.

AU - Lavrut, J.

AU - Le, L. T.T.

AU - Lessa, M.

AU - Levato, G.

AU - Li, J.

AU - Lieberman, P.

AU - Lipiec, A.

AU - Lipworth, B.

AU - Lodrup Carlsen, K. C.

AU - Louis, R.

AU - Lourenço, O.

AU - Luna-Pech, J. A.

AU - Magnan, A.

AU - Mahboub, B.

AU - Maier, D.

AU - Mair, A.

AU - Majer, I.

AU - Malva, J.

AU - Mandajieva, E.

AU - Manning, P.

AU - O'Hehir, R. E.

AU - Puy, R.

AU - Zubrinich, C.

AU - the MASK study groupJr

N1 - Funding Information: Dr Bousquet reports personal fees from Chiesi, Cipla, Hikma, Menarini, Mundipharma, Mylan, Novartis, Purina, Sanofi‐Aventis, Takeda, Teva, Uriach, other from KYomed‐Innov, outside the submitted work. Dr Bosnic‐Anticevich reports grants from TEVA, personal fees from TEVA, AstraZeneca, Boehringer Ingelheim, GSK, Sanofi, Mylan, outside the submitted work. Dr Cardona reports personal fees from ALK, Allergopharma, Allergy Therapeutics, Diater, LETI, Thermofisher, Stallergenes, outside the submitted work. Dr Fonseca being a partner in a company developing mobile technologies for monitoring airways diseases. Dr Hellings reports grants and personal fees from Mylan, during the conduct of the study; personal fees from Sanofi, Allergopharma, Stallergenes, outside the submitted work. Dr Ivancevich reports personal fees from Faes Farma, Eurofarma Argentina, other from Sanofi, Laboratorios Casasco, personal fees from, outside the submitted work. Dr Kuna reports personal fees from Adamed, AstraZeneca, Boehringer Ingelheim, Hal, Chiesi, Novartis, Berlin Chemie Menarini, outside the submitted work. Dr Kvedariene reports personal fees from GSK, non‐financial support from StallergenGreer, Mylan, AstraZeneca, Dimuna, Norameda, outside the submitted work. Dr Larenas Linnemann reports personal fees from Amstrong, Astrazeneca, Boehringer Ingelheim, Chiesi, DBV Technologies, Grunenthal, GSK, MEDA, Menarini, MSD, Novartis, Pfizer, Novartis, Sanofi, Siegfried, UCB. grants from Sanofi, Astrazeneca, Novartis, UCB, GSK, TEVA, Boehringer Ingelheim, Chiesi.outside the submitted work. Dr MULLOL reports personal fees from SANOFI‐Genzyme‐Regeneron, ALK‐Abelló A/S, Menarini Group, MSD, GlaxoSmithKline, Novartis, GENENTECH ‐ Roche_Novartis, grants and personal fees from UCB Pharma, MYLAN‐MEDA Pharma, URIACH Group, outside the submitted work. Dr Papadopoulos reports personal fees from Novartis, Nutricia, HAL, MENARINI/FAES FARMA, SANOFI, MYLAN/MEDA, BIOMAY, AstraZeneca, GSK, MSD, ASIT BIOTECH, Boehringer Ingelheim, grants from Gerolymatos International SA, Capricare, outside the submitted work. Dr Bousquet reports personal fees from Chiesi, Cipla, Hikma, Menarini, Mundipharma, Mylan, Novartis, Purina, Sanofi‐Aventis, Takeda, Teva, Uriach, other from KYomed‐Innov, outside the submitted work. Dr Pfaar reports personal fees from MEDA Pharma/MYLAN, ASIT Biotech Tools SA Laboratorios LETI/LETI Pharma, Anergis S.A, Mobile Chamber Experts (a GALEN Partner), Indoor Biotechnologies, Astellas Pharma Global, grants and personal fees from ALK‐Abelló, Allergopharma, Stallergenes Greer, HAL Allergy Holding BV/HAL Allergie GmbH, Bencard Allergie GmbH/Allergy Therapeutics, Lofarma, grants from Biomay, Nuvo, Circassia, from, Glaxo Smith Kline, outside the submitted work. 2 Publisher Copyright: © 2020 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.

PY - 2020/7/1

Y1 - 2020/7/1

N2 - Background: In allergic rhinitis, a relevant outcome providing information on the effectiveness of interventions is needed. In MASK-air (Mobile Airways Sentinel Network), a visual analogue scale (VAS) for work is used as a relevant outcome. This study aimed to assess the performance of the work VAS work by comparing VAS work with other VAS measurements and symptom-medication scores obtained concurrently. Methods: All consecutive MASK-air users in 23 countries from 1 June 2016 to 31 October 2018 were included (14 189 users; 205 904 days). Geolocalized users self-assessed daily symptom control using the touchscreen functionality on their smart phone to click on VAS scores (ranging from 0 to 100) for overall symptoms (global), nose, eyes, asthma and work. Two symptom-medication scores were used: the modified EAACI CSMS score and the MASK control score for rhinitis. To assess data quality, the intra-individual response variability (IRV) index was calculated. Results: A strong correlation was observed between VAS work and other VAS. The highest levels for correlation with VAS work and variance explained in VAS work were found with VAS global, followed by VAS nose, eye and asthma. In comparison with VAS global, the mCSMS and MASK control score showed a lower correlation with VAS work. Results are unlikely to be explained by a low quality of data arising from repeated VAS measures. Conclusions: VAS work correlates with other outcomes (VAS global, nose, eye and asthma) but less well with a symptom-medication score. VAS work should be considered as a potentially useful AR outcome in intervention studies.

AB - Background: In allergic rhinitis, a relevant outcome providing information on the effectiveness of interventions is needed. In MASK-air (Mobile Airways Sentinel Network), a visual analogue scale (VAS) for work is used as a relevant outcome. This study aimed to assess the performance of the work VAS work by comparing VAS work with other VAS measurements and symptom-medication scores obtained concurrently. Methods: All consecutive MASK-air users in 23 countries from 1 June 2016 to 31 October 2018 were included (14 189 users; 205 904 days). Geolocalized users self-assessed daily symptom control using the touchscreen functionality on their smart phone to click on VAS scores (ranging from 0 to 100) for overall symptoms (global), nose, eyes, asthma and work. Two symptom-medication scores were used: the modified EAACI CSMS score and the MASK control score for rhinitis. To assess data quality, the intra-individual response variability (IRV) index was calculated. Results: A strong correlation was observed between VAS work and other VAS. The highest levels for correlation with VAS work and variance explained in VAS work were found with VAS global, followed by VAS nose, eye and asthma. In comparison with VAS global, the mCSMS and MASK control score showed a lower correlation with VAS work. Results are unlikely to be explained by a low quality of data arising from repeated VAS measures. Conclusions: VAS work correlates with other outcomes (VAS global, nose, eye and asthma) but less well with a symptom-medication score. VAS work should be considered as a potentially useful AR outcome in intervention studies.

KW - asthma

KW - MASK

KW - rhinitis

KW - score

KW - visual analogue scale

UR - http://www.scopus.com/inward/record.url?scp=85081893884&partnerID=8YFLogxK

U2 - 10.1111/all.14204

DO - 10.1111/all.14204

M3 - Article

C2 - 31995656

AN - SCOPUS:85081893884

SN - 0105-4538

VL - 75

SP - 1672

EP - 1688

JO - Allergy

JF - Allergy

IS - 7